emerg
reemerg
pathogen
identifi
last
year
institut
medicin
issu
report
defin
emerg
infecti
diseas
medicin
complac
infecti
diseas
despit
alarm
bell
infect
human
immunodefici
viru
molecular
tool
proven
use
discov
character
emerg
virus
bacteria
sin
nombr
viru
hantavir
pulmonari
syndrom
hepat
c
viru
bartonella
hensela
cat
scratch
diseas
bacillari
angiomatosi
anaplasma
phagocytophilum
human
granulocytotrop
anaplasmosi
feasibl
appli
molecular
diagnost
danger
fastidi
uncultiv
agent
convent
test
yield
time
diagnos
achiev
proof
concept
mani
agent
widespread
use
costeffect
valid
commerci
assay
yet
occur
review
present
repres
emerg
viral
respiratori
infect
hemorrhag
fever
hepatitid
well
bacteri
parasit
zoonot
gastrointestin
pulmonari
infect
agent
characterist
epidemiolog
clinic
manifest
diagnost
method
tabul
anoth
emerg
virus
five
emerg
bacteria
ongo
challeng
field
molecular
diagnost
appli
contemporari
knowledg
facilit
agent
diagnosi
well
discoveri
novel
pathogen
j
mol
diagn
realiti
everi
infecti
diseas
emerg
time
past
smallpox
like
jump
rodent
host
human
maintain
humantohuman
transmiss
agricultur
urban
center
support
larg
enough
popul
sustain
continu
spread
without
exhaust
suscept
host
mycobacterium
tuberculosi
may
evolv
bovi
caus
human
infect
domest
cattl
extens
humantohuman
transmiss
diseas
occur
condit
human
crowd
industri
revolut
despit
optimist
statement
us
surgeon
gener
war
infecti
diseas
emerg
infecti
diseas
ceas
never
inde
marburg
hemorrhag
fever
appear
lassa
fever
year
later
approxim
new
infecti
diseas
agent
identifi
last
year
identif
reflect
condit
favor
spread
infecti
diseas
scientif
advanc
enabl
discoveri
character
microb
condit
favor
emerg
includ
human
behavior
eg
cyclosporiasi
new
technic
product
eg
toxic
shock
syndrom
blood
transfus
eg
hepat
c
viru
movement
exot
anim
eg
monkeypox
nosocomi
transmiss
creat
larg
outbreak
eg
ebola
hemorrhag
fever
deforest
eg
venezuelan
hemorrhag
fever
increas
popul
reservoir
vector
speci
eg
whitetail
deer
amblyomma
americanium
tick
transmit
human
monocytotrop
ehrlichiosi
discoveri
bartonella
hensela
allow
associ
longknown
ill
cat
scratch
diseas
none
agent
truli
new
except
knowledg
emerg
agent
compris
virus
tabl
bacteria
tabl
protozoa
emerg
infecti
diseas
includ
respiratori
central
nervou
system
enter
infect
viral
hemorrhag
fever
hepatitid
system
bacteri
infect
human
retrovir
novel
herp
viral
infect
use
molecular
method
detect
identif
character
infecti
agent
gener
gain
import
clinic
microbiolog
laboratori
emerg
reemerg
pathogen
pose
sever
chal
leng
diagnosi
treatment
public
health
surveil
identif
emerg
pathogen
convent
method
difficult
timeconsum
due
novel
natur
agent
requir
larg
array
techniqu
includ
cell
cultur
inocul
anim
cultiv
use
artifici
media
histopatholog
evalu
tissu
avail
serolog
techniqu
use
surrog
antigen
look
back
past
epidem
outbreak
caus
previous
unknown
infecti
agent
realiz
identif
character
new
infecti
agent
take
year
decad
even
centuri
time
frame
decreas
week
month
use
power
molecular
techniqu
illustr
identif
sever
acut
respiratori
syndrom
coronaviru
sarscov
within
week
first
case
report
discoveri
new
hantaviru
north
america
detect
bacteria
etiolog
pathogen
human
infect
ehrlichia
chaffeensi
anaplasma
phagocytophilum
human
monocytotrop
ehrlichiosi
human
granulocytotrop
anaplasmosi
respect
molecular
techniqu
offer
sever
advantag
convent
method
includ
high
sensit
specif
speed
eas
standard
autom
advantag
includ
identif
novel
noncultiv
slowli
grow
organ
strain
type
epidemiolog
studi
antimicrobi
suscept
determin
monitor
treatment
measur
bacteri
viral
load
exampl
provid
review
repres
emerg
viral
respiratori
infect
hemorrhag
fever
hepatitid
well
bacteri
parasit
zoonot
gastrointestin
pulmonari
infect
molecular
assay
prefer
method
identif
new
strain
influenza
infect
nucleotid
sequenc
analys
h
n
gene
confirm
viru
isol
avian
subtyp
revers
transcriptasepolymeras
chain
reaction
rtpcr
use
specif
hemagglutinin
gene
sequenc
influenza
use
subsequ
human
case
report
period
limit
humantohuman
transmiss
viru
potenti
mutat
reassort
gener
virus
could
highli
lethal
capabl
transmit
effici
person
person
believ
occur
influenza
pandem
influenza
pathognomon
symptom
diagnosi
base
clinic
sign
correct
twothird
patient
therefor
sensit
rapid
laboratori
test
requir
guid
antivir
use
influenza
viru
replic
detect
respiratori
secret
viral
load
remain
high
hour
rtpcr
increasingli
provid
definit
diagnosi
especi
earli
infect
along
antigen
detect
recent
multiplex
strategi
respiratori
virus
includ
influenza
virus
develop
assay
provid
rapid
sensit
test
respiratori
viral
infect
first
pandem
centuri
caus
sarscov
emerg
southern
china
novemb
spread
countri
five
contin
confirm
case
death
month
rtpcr
clone
sequenc
contribut
identif
novel
coronaviru
sarscov
spread
respiratori
secret
airborn
transmiss
although
market
anim
believ
sourc
human
transmiss
bat
suspect
sylvat
reservoir
viru
earli
ill
sar
distinguish
common
respiratori
infect
base
clinic
symptom
sarscov
caus
high
mortal
thu
time
sensit
specif
diagnosi
need
prevent
spread
contagi
diseas
sar
epidem
pcrbase
molecular
test
help
abil
rapidli
screen
mani
virus
identif
sarscov
specif
rtpcr
serolog
assay
develop
detect
infect
appear
antibodi
risk
transmiss
greatest
sarscov
detect
rtpcr
nasopharyng
aspir
patient
initi
present
day
viral
rna
also
detect
rtpcr
stool
sampl
day
diseas
onset
contrast
sarscov
igg
seroconvers
began
day
detect
day
day
onset
combin
rtpcr
immunoassay
diagnos
patient
day
use
nasopharyng
aspir
stool
sampl
respect
coronavirus
envelop
positivestrand
rna
virus
hcov
subtyp
identifi
caus
common
cold
shortli
outbreak
sar
two
addit
hcov
identifi
four
hcov
mostli
caus
mild
upper
respiratori
ill
sore
throat
rhinorrhea
cough
fever
account
estim
onethird
common
cold
case
howev
young
children
immunocompromis
adult
hcov
caus
sever
although
usual
lifethreaten
lower
respiratori
tract
infect
includ
bronchiol
pneumonia
tradit
viral
cultur
immunolog
assay
use
detect
howev
viral
cultur
often
take
week
complet
fastidi
growth
requir
immunolog
assay
rel
insensit
molecular
assay
becom
essenti
diagnost
tool
sensit
specif
detect
hcov
sever
consensu
subtypespecif
molecular
assay
develop
either
four
hcov
genet
variabl
hcov
make
detect
circul
strain
technic
challeng
exampl
pancov
primer
use
gerna
et
al
fail
detect
approxim
circul
strain
thu
detect
maxim
number
hcov
specif
primer
use
result
confirm
second
set
primer
falseneg
result
occur
assay
sensit
actual
viral
load
specimen
anoth
potenti
technic
issu
fals
identif
crossreact
hcov
strain
etiolog
agent
respiratori
infect
identifi
half
case
identif
hmpv
exemplifi
molecular
diagnost
assay
aid
identif
new
pathogen
use
randomli
prime
pcr
clone
sequenc
van
den
hoogen
obtain
genom
sequenc
hmpv
previous
unknown
paramyxoviru
nasopharyng
aspir
children
respiratori
tract
ill
rtpcr
detect
hmpv
subject
respiratori
symptom
age
year
nearli
individu
antibodi
hmpv
hmpv
worldwid
distribut
circul
princip
winter
spring
temper
climat
viru
associ
flulik
syndrom
otiti
media
croup
exacerb
asthma
obstruct
pulmonari
diseas
pneumonia
among
immunocompromis
patient
includ
transplant
recipi
elderli
infant
hmpv
infect
commonli
caus
sever
diseas
rtpcr
method
choic
diagnosi
hmpv
infect
hmpv
grow
poorli
cell
cultur
serolog
test
low
specif
hmpv
infect
almost
univers
childhood
infecti
agent
identifi
multiplex
method
develop
comprehens
detect
infecti
agent
clinic
laboratori
increasingli
face
question
whether
identifi
agent
respons
diseas
hbov
provid
exampl
hbov
newli
discov
human
parvoviru
first
identifi
random
pcrclone
techniqu
respiratori
sampl
hbov
worldwid
distribut
high
preval
although
detect
primarili
infant
children
acut
respiratori
tract
infect
hbov
found
concurr
infecti
agent
case
similar
symptom
produc
coinfect
agent
question
whether
hbov
caus
respiratori
tract
diseas
coincident
find
detect
hbov
possibl
pcr
molecular
assay
anim
model
method
viru
cultur
avail
fulfil
koch
postul
prove
diseas
causat
hbov
previous
found
preval
among
children
acut
wheez
exacerb
asthma
regamey
colleagu
prospect
analyz
first
acut
respiratori
infect
birth
cohort
healthi
swiss
neonat
april
decemb
hbov
identifi
five
infant
mild
diseas
none
hospit
four
five
infant
hbov
associ
respiratori
virus
anoth
studi
volz
et
al
investig
hbov
infect
hospit
pediatr
patient
one
winter
hbov
dna
detect
nasopharyng
aspir
symptomat
hospit
children
major
patient
sever
ill
radiolog
confirm
pneumonia
requir
oxygen
supplement
five
six
patient
pneumonia
hbov
agent
detect
suggest
hbov
innoc
bystand
rather
caus
sever
respiratori
tract
infect
infant
young
children
nevertheless
futur
studi
necessari
character
clinic
ill
establish
patholog
role
viru
viral
hemorrhag
fever
syndrom
caus
heterogen
group
virus
common
featur
singlestrand
negativesens
rna
genom
lipid
envelop
virus
belong
famili
arenavirida
bunyavirida
filovirida
flavivirida
infect
human
usual
high
casefat
ratio
infect
geograph
limit
owe
ecolog
factor
specif
viral
host
patient
develop
high
fever
malais
sever
headach
myalgia
follow
microvascular
leakag
progress
bleed
cardiovascular
compromis
hypovolem
shock
pulmonari
edema
acut
renal
failur
sever
hepat
injuri
neurolog
involv
tabl
viral
isol
serum
plasma
bodi
fluid
perform
safe
laboratori
viremia
usual
high
present
except
hantavirus
isol
perform
cell
cultur
initi
recoveri
isol
laboratori
anim
specif
identif
isol
perform
pcr
immunofluoresc
use
specif
antibodi
detect
electron
microscopi
organ
requir
high
concentr
viral
particl
particlesml
antigen
detect
possibl
igm
antibodi
usual
elev
present
often
detect
enzymelink
immunosorb
assay
immunohistochem
demonstr
viral
antigen
allow
diagnosi
tissu
sampl
obtain
preor
postmortem
rtpcr
success
appli
pathogen
detect
util
regular
realtim
pcr
howev
virus
heterogen
univers
target
avail
therefor
primer
specif
famili
possibl
multiplex
realtim
format
limit
modifi
nucleic
acid
amplif
techniqu
nest
seminest
pcr
increas
sensit
specif
realtim
pcr
assay
also
develop
recent
numer
convent
pcr
assay
advantag
realtim
pcr
includ
less
risk
amplicon
contamin
use
detect
probe
instead
sybr
green
sybr
gold
increas
specif
clinic
sensit
pcr
rang
depend
pathogen
lowest
crimeancongo
hemorrhag
fever
analyt
sensit
realtim
pcr
estim
low
pfuml
filovirus
pcr
target
filovirus
includ
polymeras
gene
highli
conserv
glycoprotein
gene
detect
subtyp
ebola
marburg
viru
nucleoprotein
gene
bunyaviru
crimeancongo
hemorrhag
fever
viru
detect
target
rna
segment
rift
valley
fever
viru
target
segment
clinic
sensit
bunyavirus
high
filovirus
close
arenavirus
target
rna
segment
howev
segment
highli
variabl
sever
pcr
primer
requir
detect
strain
primer
l
segment
also
design
primer
yellow
fever
viru
flaviviru
target
highli
conserv
gene
dengu
viru
primer
design
detect
subtyp
differenti
among
four
subtyp
molecular
assay
play
import
role
identif
surveil
routin
clinic
diagnosi
manag
hepat
c
delta
e
viral
infect
hdv
requir
hepat
b
viru
hbv
complet
life
cycl
eukaryot
host
cell
sinc
hdv
replic
depend
hbsag
packag
hdv
genom
exact
classif
viru
remain
elus
relat
viroid
plant
satellit
virus
simpl
infecti
rna
molecul
infect
hdv
occur
either
coinfect
hbv
superinfect
patient
alreadi
infect
hbv
virus
present
risk
sever
diseas
fourfold
greater
patient
infect
hbv
alon
spectrum
diseas
rang
asymptomat
endstag
liver
diseas
cirrhosi
addit
superinfect
patient
risk
develop
acut
fulmin
hepat
measur
hdv
antibodi
employ
radioimmunoassay
enzymelink
immunosorb
assay
superinfect
patient
igg
igm
respons
usual
strong
coinfect
patient
produc
igg
igm
main
marker
hdv
infect
antihdv
igm
correl
activ
liver
inflamm
progress
cirrhosi
hdv
antigen
detect
earli
stage
diseas
antihdv
antibodi
titer
rise
antigen
mask
nuclear
hdv
detect
tissu
immunohistochemistri
situ
hybrid
prolong
infect
less
like
viru
detect
tissu
convent
realtim
revers
transcript
amplif
assay
perform
detect
hdv
serum
research
laboratori
primer
amplifi
known
clade
type
seven
target
ribozym
region
genom
antigenom
hdv
analyt
sensit
realtim
assay
approxim
copiesml
quantit
analysi
use
follow
patient
treatment
hev
transmit
enter
common
tropic
subtrop
region
chronic
sequela
develop
infect
fulmin
hepat
occur
especi
pregnant
women
diseas
sever
third
trimest
mortal
approach
hev
nonenvelop
singlestrand
positivesens
rna
viru
morpholog
closest
relat
virus
calicivirida
famili
howev
genom
organ
closer
rubellaviru
detect
specif
antibodi
convalesc
phase
igg
acut
phase
igm
employ
enzymelink
immunosorb
assay
western
immunoblot
elev
igm
titer
rise
igg
titer
suggest
acut
infect
amplif
viral
rna
serum
fece
environment
sampl
rtpcr
regular
realtim
format
avail
select
research
center
pcr
test
perform
earli
possibl
sinc
fecal
excret
viremia
shortliv
primer
target
viral
helicas
polymeras
part
end
open
read
frame
assay
sensit
specif
method
offer
effect
diagnosi
ill
unfortun
occur
develop
countri
research
method
usual
unavail
molecular
approach
detect
emerg
bacteri
pathogen
steadili
evolv
although
mani
laboratorydevelop
lll
molecular
assay
agent
primari
laboratori
diagnosi
emerg
bacteri
agent
still
reli
mainli
convent
diagnost
method
tabl
molecular
diagnost
often
use
confirm
convent
detect
method
direct
cultur
serolog
biochem
identif
microscop
visual
laboratorydevelop
molecular
assay
develop
nearli
emerg
bacteri
pathogen
although
sensit
fdaapprov
assay
may
avail
howev
remain
challeng
involv
ideal
diagnost
specimen
standard
pcr
protocol
laboratori
contamin
variabl
pathogen
dna
sensit
compar
convent
assay
cost
effect
must
address
molecular
detect
becom
prefer
diagnost
method
nevertheless
molecular
assay
would
advantag
sever
emerg
pathogen
isol
convent
laboratori
caus
diseas
clinic
difficult
diagnos
requir
convent
diagnost
method
labori
technic
challeng
requir
special
biocontain
facil
ehrlichia
anaplasma
ticktransmit
obligateintracellular
gramneg
bacteria
caus
three
distinct
emerg
human
zoonos
describ
last
two
decad
e
chaffeensi
e
ewingii
etiolog
agent
human
monocytotrop
ehrlichiosi
ehrlichiosi
ewingii
respect
phagocytophilum
caus
human
granulocytotrop
anaplasmosi
human
monocytotrop
ehrlichiosi
ehrlichiosi
ewingii
human
granulocytotrop
anaplasmosi
season
may
juli
peak
incid
manifest
undifferenti
febril
ill
human
monocytotrop
ehrlichiosi
lifethreaten
diseas
result
hospit
larg
proport
immunocompet
patient
case
fatal
rate
wherea
ehrlichiosi
ewingii
report
primarili
immunocompromis
individu
milder
diseas
sever
human
granulocytotrop
anaplasmosi
agedepend
mani
patient
requir
hospit
microscop
visual
morula
peripher
blood
leukocyt
may
simplest
test
also
least
sensit
current
serolog
test
use
method
excel
sensit
specif
reliabl
unfortun
antibodi
usual
absent
first
week
symptom
onset
convers
pcr
use
multipl
gene
target
sensit
method
cultureconfirm
case
human
monocytotrop
ehrlichiosi
earli
acut
phase
therefor
advantag
molecular
detect
ehrlichia
anaplasma
diagnosi
develop
antibodi
detect
ehrlichia
speci
uncultiv
e
ewingii
although
commerci
pcr
assay
ehrlichios
develop
realtim
pcr
assay
capabl
simultan
rapid
sensit
detect
copi
medic
import
ehrlichia
anaplasma
acut
phase
diseas
develop
could
readili
use
clinic
molecular
diagnost
laboratori
spot
fever
group
rickettsia
rickettsia
arthropodborn
obligateintracellular
bacteria
primarili
infect
microvasculatur
spot
fever
group
rickettsia
mainli
ticktransmit
pathogen
includ
rickettsia
rickettsii
r
japonica
r
honei
r
africa
r
parkeri
r
slovaca
r
feli
transmit
flea
spot
fever
group
rickettsia
includ
lifethreaten
infect
symptom
includ
fever
sever
headach
malais
myalgia
nausea
vomit
abdomin
pain
diagnosi
rickettsi
infect
accomplish
number
convent
techniqu
includ
isol
serolog
serolog
use
diagnost
assay
howev
patient
develop
antibodi
earli
stage
diseas
thu
serolog
use
import
therapeut
decis
requir
isol
procedur
labori
timeconsum
requir
appropri
biocontain
refer
laboratori
special
train
rickettsiologist
immunohistochem
detect
spot
fever
group
rickettsia
eschar
rash
sensit
specif
molecular
diagnost
advantag
acut
infect
develop
specif
antibodi
howev
molecular
detect
avail
refer
laboratori
laboratorydevelop
pcr
assay
develop
detect
spot
fever
group
rickettsia
realtim
pcr
use
sever
gene
target
glta
ompa
ompb
appear
improv
analyt
sensit
howev
sensit
assay
remain
valid
clinic
context
chlamydia
obligateintracellular
gramneg
bacteria
replic
within
endosom
vacuol
host
cell
chlamydophila
pneumonia
emerg
earli
new
caus
communityacquir
pneumonia
bronchiti
sinus
case
primarili
children
year
age
serolog
evid
indic
c
pneumonia
infect
occur
worldwid
seropreval
greater
among
adult
diagnosi
c
pneumonia
infect
usual
accomplish
serolog
test
center
diseas
control
prevent
consid
microimmunofluoresc
test
refer
standard
technic
difficult
timeconsum
lack
sensit
compar
pcr
cell
cultur
isol
cell
cultur
isol
chlamydia
also
technic
complex
requir
week
obtain
result
furthermor
cell
cultur
isol
microimmunoflouresc
use
highthroughput
screen
thu
molecular
assay
noncultur
method
would
clinic
advantag
numer
laboratorydevelop
pcr
assay
report
none
fulli
valid
clinic
context
furthermor
lack
standard
interlaboratori
variat
c
pneumonia
pcr
assay
make
difficult
determin
compar
sensit
specif
one
commerci
pcr
assay
develop
report
high
analyt
sensit
one
copi
dna
specif
borrelia
burgdorferi
borrelia
ticktransmit
spirochet
maintain
natur
divers
mammalian
reservoir
rodent
primari
host
b
burgdorferi
emerg
tickborn
diseas
public
health
import
outbreak
epidem
juvenil
rheumatoid
arthriti
children
three
contigu
town
connecticut
lyme
diseas
highest
incid
northeast
connecticut
new
york
rhode
island
massachusett
new
jersey
upper
midwest
ixod
scapulari
tick
primari
vector
lyme
diseas
season
summer
earli
fall
patient
present
distinct
rash
erythema
migran
headach
stiff
neck
myalgia
arthralgia
malais
lymphadenopathi
fatigu
earli
dissemin
diseas
occur
month
later
includ
neurolog
musculoskelet
manifest
patient
develop
diseas
year
later
chronic
neurolog
musculoskelet
manifest
diagnosi
lyme
borreliosi
accomplish
use
cultur
microscopi
detect
dna
protein
antib
burgdorferi
antibodi
antibodi
detect
insensit
earli
infect
allow
distinguish
activ
inact
infect
direct
cultur
liquid
medium
use
detect
activ
infect
sensit
low
numer
pcr
assay
develop
gold
standard
molecular
assay
emerg
sensit
pcr
assay
depend
assay
also
clinic
specimen
evalu
highest
pcr
sensit
report
skin
biopsi
synovi
fluid
contrast
sensit
pcr
blood
cerebrospin
fluid
low
thu
pcr
assay
wide
embrac
laboratori
diagnosi
lyme
diseas
helicobact
name
speci
motil
spiral
curveshap
gramneg
bacteria
resid
gastrointestin
tract
human
anim
h
pylori
accept
major
caus
peptic
ulcer
diseas
design
human
carcinogen
world
health
organ
adult
serolog
evid
infect
age
year
h
pylori
infect
caus
acut
gastriti
chronic
infect
occur
mani
individu
produc
gastriti
duoden
gastric
duoden
ulcer
multifoc
atroph
gastriti
gastric
adenocarcinoma
h
pylori
infect
diagnos
use
varieti
convent
molecular
techniqu
fall
short
consid
gold
standard
invas
test
usual
consid
refer
method
direct
cultur
refer
method
often
unavail
difficult
specimen
transport
condit
strict
infect
also
diagnos
histolog
examin
ureas
test
noninvas
test
ureas
breath
test
serolog
detect
stool
immunoenzymat
molecular
techniqu
immunoassay
direct
detect
h
pylori
antigen
fecal
sampl
us
food
drug
administrationapprov
high
sensit
specif
cost
effect
routin
screen
serolog
high
sensit
specif
ureas
breath
test
wide
use
greater
sensit
specif
molecular
test
h
pylori
commerci
avail
mani
pcr
assay
includ
realtim
pcr
provid
rapid
detect
quantif
organ
identif
mutat
associ
antibiot
resist
howev
standard
lack
molecular
diagnost
may
costeffect
altern
highli
sensit
specif
immunoassay
ureas
breath
test
cryptosporidium
parvum
first
diagnos
human
pathogen
two
immunocompromis
patient
persist
diarrhea
largest
outbreak
involv
person
milwauke
immunocompromis
patient
eg
acquir
immunodefici
syndrom
debilit
diarrhea
persist
week
month
cryptosporidiosi
caus
childhood
diarrhea
endem
develop
countri
convent
diagnosi
examin
direct
wet
mount
fecal
specimen
increas
sensit
concentr
oocyst
detect
use
modifi
acid
fast
stain
auramineo
stain
analyt
sensit
immunoassay
concentr
fecal
sampl
approxim
oocystsg
stool
sever
laboratorydevelop
standard
realtim
pcr
assay
target
rrna
outer
wall
protein
gene
sensit
rang
specif
approach
analyt
sensit
estim
oocystsml
liquid
stool
microsporidia
microsporidia
sporeform
obligateintracellular
protozoa
infect
intestin
liver
kidney
brain
tissu
genera
contain
speci
encephalitozoon
enterocytozoon
pleistophora
brachiola
nosema
trachipleistophora
vittaforma
microsporidium
human
pathogen
commonli
enterocytozoon
bieneusi
encephalitozoon
intestinali
microsporidios
increas
incid
patient
acquir
immunodefici
syndrom
accept
convent
method
stool
examin
weber
chromotropebas
stain
ultraviolet
visual
achiev
use
calcofluor
white
uvitex
analyt
sensit
around
sporesml
fluoresc
techniqu
slightli
sensit
slightli
less
specif
chromotropebas
techniqu
cytolog
histolog
diagnosi
extraintestin
microsporidiosi
employ
modifi
trichrom
gram
giemsa
tissuebas
gram
stain
brownhopp
chemofluoresc
agent
immunofluoresc
techniqu
use
either
polyclon
monoclon
antibodi
direct
spore
antigen
polar
tube
protein
also
use
bodi
fluid
biopsi
sensit
appear
somewhat
lower
routin
stain
method
commerci
molecular
test
microsporidiosi
avail
molecular
assay
use
refer
laboratori
pcrbase
test
identifi
microsporidia
speci
level
stool
specimen
intestin
biopsi
tissu
microsporidia
eukaryot
genom
size
overlap
bacteria
mb
furthermor
rrna
gene
close
relat
prokaryot
rrna
rrna
separ
intergen
spacer
pcr
target
usual
small
larg
subunit
rrna
gene
intergen
spacer
region
overal
sensit
pcr
rang
light
microscop
method
routin
stain
procedur
overal
sensit
specif
respect
analyt
sensit
microscopi
sporesg
fece
pcr
around
sporesg
cyclospora
cyclospora
cayetanensi
first
describ
human
pathogen
foodborn
outbreak
occur
around
world
infect
occur
via
fecalor
rout
ingest
contamin
water
produc
humantohuman
infect
made
less
like
long
sporul
time
least
day
shed
fece
case
occur
tropic
subtrop
countri
diseas
character
wateri
diarrhea
cramp
bloat
well
weight
loss
prolong
treat
diarrhea
persist
week
month
immunocompromis
patient
diseas
last
sever
month
oocyst
visual
use
modifi
acidfast
stain
modifi
hot
safranin
techniqu
similar
cryptosporidium
twice
diamet
oocyst
also
visual
ultraviolet
light
due
autofluoresc
compar
ultraviolet
detect
sensit
acidfast
techniqu
c
cayetanesi
observ
intracellularli
smallbowel
biopsi
pcr
detect
human
fece
produc
water
employ
primer
target
intern
transcrib
spacer
region
analyt
sensit
oocystsg
fece
balamuthia
mandrillari
acanthamoeba
balamuthia
caus
granulomat
ameb
enceph
naegleria
fowleri
primari
ameb
meningoenceph
granulomat
ameb
enceph
common
immunocompromis
patient
occur
worldwid
balamuthia
isol
first
baboon
die
granulomat
ameb
enceph
isol
perform
mammalian
cell
cultur
initi
site
infect
possibl
lower
respiratori
tract
respiratori
sinus
skin
dissemin
central
nervou
system
diagnosi
base
histolog
identif
brain
tissu
differenti
acanthamoeba
balamuthia
difficult
specif
antibodi
appli
research
laboratori
immunohistochemistri
pcr
test
target
mitochondri
rrna
gene
rrna
gene
analyt
sensit
use
mitochondri
target
low
amoeba
per
reaction
mixtur
due
abund
target
present
ameb
cell
contain
hundr
thousand
mitochondria
assay
effect
three
case
use
brain
tissu
three
case
use
cerebrospin
fluid
multiplex
approach
realtim
pcr
platform
differenti
among
three
speci
respons
ameb
enceph
use
taqman
probe
specif
speci
test
rapid
specif
analyt
sensit
one
ameb
cell
per
reaction
mixtur
futur
bright
molecular
test
emerg
pathogen
avail
molecular
diagnost
test
pointofcar
test
far
away
technolog
result
time
accur
inexpens
diagnosi
effect
treatment
infecti
diseas
public
health
implic
unlimit
compani
develop
pointofcar
test
instrument
molecular
diagnosi
infecti
diseas
aim
miniatur
analyt
method
build
small
walkaway
instrument
requir
minim
oper
therefor
high
complex
associ
molecular
test
would
diminish
limit
factor
hospit
diagnost
laboratori
fact
mani
instrument
would
avail
deploy
remot
area
promis
detect
system
use
experiment
pointofcar
test
instrument
includ
realtim
pcr
nanoparticl
probebas
bioluminesc
realtim
amplif
microarray
micropump
technolog
